ArticleThe oncologist2020

Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.

Federica Miglietta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.